Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.34 |
| ▸ | JAK1 | P23458 | 12/20 | 0.34 |
| ▸ | TYK2 | P29597 | 7/20 | 0.34 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504475 | 0.91 | JAK2 (0.38) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1504400 | 0.91 | JAK2 (0.39) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1504359 | 0.90 | JAK2 (0.35) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1504362 | 0.90 | JAK2 (0.39) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9921776 | 0.89 | JAK2 (0.41) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9921773 | 0.89 | JAK2 (0.41) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1504434 | 0.89 | JAK2 (0.41) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1504514 | 0.88 | JAK2 (0.48) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1504435 | 0.87 | JAK1 (0.41) | JAK2JAK1TYK2 | |
| SCHEMBL9918768 | 0.80 | JAK1 (0.30) | JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470537-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.